| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0004 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0006 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0006 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0007 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.003 |